Plasticity of the Immune System in Children Following Treatment Interruption in HIV-1 Infection

It is intriguing that, unlike adults with HIV-1, children with HIV-1 reach a greater CD4+ T cell recovery following planned treatment cessation. The reasons for the better outcomes in children remain unknown but may be related to increased thymic output and diversity of T cell receptor repertoires....

Full description

Bibliographic Details
Main Authors: Katrine Schou Sandgaard, Ben Margetts, Teresa Attenborough, Triantafylia Gkouleli, Stuart Adams, Mette Holm, Diana Gibb, Deena Gibbons, Carlo Giaquinto, Anita De Rossi, Alasdair Bamford, Paolo Palma, Benny Chain, Athina S. Gkazi, Nigel Klein
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.643189/full
id doaj-79f0d43cd57a4d539ba69043ab600565
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Katrine Schou Sandgaard
Katrine Schou Sandgaard
Ben Margetts
Teresa Attenborough
Teresa Attenborough
Triantafylia Gkouleli
Stuart Adams
Mette Holm
Diana Gibb
Deena Gibbons
Carlo Giaquinto
Anita De Rossi
Anita De Rossi
Alasdair Bamford
Alasdair Bamford
Alasdair Bamford
Paolo Palma
Benny Chain
Athina S. Gkazi
Nigel Klein
spellingShingle Katrine Schou Sandgaard
Katrine Schou Sandgaard
Ben Margetts
Teresa Attenborough
Teresa Attenborough
Triantafylia Gkouleli
Stuart Adams
Mette Holm
Diana Gibb
Deena Gibbons
Carlo Giaquinto
Anita De Rossi
Anita De Rossi
Alasdair Bamford
Alasdair Bamford
Alasdair Bamford
Paolo Palma
Benny Chain
Athina S. Gkazi
Nigel Klein
Plasticity of the Immune System in Children Following Treatment Interruption in HIV-1 Infection
Frontiers in Immunology
HIV-1
T cells
thymic output
antiretroviral treatment interruption
T cell receptor
immune repertoires
author_facet Katrine Schou Sandgaard
Katrine Schou Sandgaard
Ben Margetts
Teresa Attenborough
Teresa Attenborough
Triantafylia Gkouleli
Stuart Adams
Mette Holm
Diana Gibb
Deena Gibbons
Carlo Giaquinto
Anita De Rossi
Anita De Rossi
Alasdair Bamford
Alasdair Bamford
Alasdair Bamford
Paolo Palma
Benny Chain
Athina S. Gkazi
Nigel Klein
author_sort Katrine Schou Sandgaard
title Plasticity of the Immune System in Children Following Treatment Interruption in HIV-1 Infection
title_short Plasticity of the Immune System in Children Following Treatment Interruption in HIV-1 Infection
title_full Plasticity of the Immune System in Children Following Treatment Interruption in HIV-1 Infection
title_fullStr Plasticity of the Immune System in Children Following Treatment Interruption in HIV-1 Infection
title_full_unstemmed Plasticity of the Immune System in Children Following Treatment Interruption in HIV-1 Infection
title_sort plasticity of the immune system in children following treatment interruption in hiv-1 infection
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2021-07-01
description It is intriguing that, unlike adults with HIV-1, children with HIV-1 reach a greater CD4+ T cell recovery following planned treatment cessation. The reasons for the better outcomes in children remain unknown but may be related to increased thymic output and diversity of T cell receptor repertoires. HIV-1 infected children from the PENTA 11 trial tolerated planned treatment interruption without adverse long-term clinical, virological, or immunological consequences, once antiretroviral therapy was re-introduced. This contrasts to treatment interruption trials of HIV-1 infected adults, who had rapid changes in T cells and slow recovery when antiretroviral therapy was restarted. How children can develop such effective immune responses to planned treatment interruption may be critical for future studies. PENTA 11 was a randomized, phase II trial of planned treatment interruptions in HIV-1-infected children (ISRCTN 36694210). In this sub-study, eight patients in long-term follow-up were chosen with CD4+ count>500/ml, viral load <50c/ml at baseline: four patients on treatment interruption and four on continuous treatment. Together with measurements of thymic output, we used high-throughput next generation sequencing and bioinformatics to systematically organize memory CD8+ and naïve CD4+ T cell receptors according to diversity, clonal expansions, sequence sharing, antigen specificity, and T cell receptor similarities following treatment interruption compared to continuous treatment. We observed an increase in thymic output following treatment interruption compared to continuous treatment. This was accompanied by an increase in T cell receptor clonal expansions, increased T cell receptor sharing, and higher sequence similarities between patients, suggesting a more focused T cell receptor repertoire. The low numbers of patients included is a limitation and the data should be interpreted with caution. Nonetheless, the high levels of thymic output and the high diversity of the T cell receptor repertoire in children may be sufficient to reconstitute the T cell immune repertoire and reverse the impact of interruption of antiretroviral therapy. Importantly, the effective T cell receptor repertoires following treatment interruption may inform novel therapeutic strategies in children infected with HIV-1.
topic HIV-1
T cells
thymic output
antiretroviral treatment interruption
T cell receptor
immune repertoires
url https://www.frontiersin.org/articles/10.3389/fimmu.2021.643189/full
work_keys_str_mv AT katrineschousandgaard plasticityoftheimmunesysteminchildrenfollowingtreatmentinterruptioninhiv1infection
AT katrineschousandgaard plasticityoftheimmunesysteminchildrenfollowingtreatmentinterruptioninhiv1infection
AT benmargetts plasticityoftheimmunesysteminchildrenfollowingtreatmentinterruptioninhiv1infection
AT teresaattenborough plasticityoftheimmunesysteminchildrenfollowingtreatmentinterruptioninhiv1infection
AT teresaattenborough plasticityoftheimmunesysteminchildrenfollowingtreatmentinterruptioninhiv1infection
AT triantafyliagkouleli plasticityoftheimmunesysteminchildrenfollowingtreatmentinterruptioninhiv1infection
AT stuartadams plasticityoftheimmunesysteminchildrenfollowingtreatmentinterruptioninhiv1infection
AT metteholm plasticityoftheimmunesysteminchildrenfollowingtreatmentinterruptioninhiv1infection
AT dianagibb plasticityoftheimmunesysteminchildrenfollowingtreatmentinterruptioninhiv1infection
AT deenagibbons plasticityoftheimmunesysteminchildrenfollowingtreatmentinterruptioninhiv1infection
AT carlogiaquinto plasticityoftheimmunesysteminchildrenfollowingtreatmentinterruptioninhiv1infection
AT anitaderossi plasticityoftheimmunesysteminchildrenfollowingtreatmentinterruptioninhiv1infection
AT anitaderossi plasticityoftheimmunesysteminchildrenfollowingtreatmentinterruptioninhiv1infection
AT alasdairbamford plasticityoftheimmunesysteminchildrenfollowingtreatmentinterruptioninhiv1infection
AT alasdairbamford plasticityoftheimmunesysteminchildrenfollowingtreatmentinterruptioninhiv1infection
AT alasdairbamford plasticityoftheimmunesysteminchildrenfollowingtreatmentinterruptioninhiv1infection
AT paolopalma plasticityoftheimmunesysteminchildrenfollowingtreatmentinterruptioninhiv1infection
AT bennychain plasticityoftheimmunesysteminchildrenfollowingtreatmentinterruptioninhiv1infection
AT athinasgkazi plasticityoftheimmunesysteminchildrenfollowingtreatmentinterruptioninhiv1infection
AT nigelklein plasticityoftheimmunesysteminchildrenfollowingtreatmentinterruptioninhiv1infection
_version_ 1721209456819175424
spelling doaj-79f0d43cd57a4d539ba69043ab6005652021-08-12T13:33:07ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-07-011210.3389/fimmu.2021.643189643189Plasticity of the Immune System in Children Following Treatment Interruption in HIV-1 InfectionKatrine Schou Sandgaard0Katrine Schou Sandgaard1Ben Margetts2Teresa Attenborough3Teresa Attenborough4Triantafylia Gkouleli5Stuart Adams6Mette Holm7Diana Gibb8Deena Gibbons9Carlo Giaquinto10Anita De Rossi11Anita De Rossi12Alasdair Bamford13Alasdair Bamford14Alasdair Bamford15Paolo Palma16Benny Chain17Athina S. Gkazi18Nigel Klein19Great Ormond Street Institute of Child Health, University College London, London, United KingdomDepartment of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, DenmarkMolecular Haematology, Great Ormond Street Hospital for Children, London, United KingdomGreat Ormond Street Institute of Child Health, University College London, London, United KingdomUCL Centre for Computation, Mathematics, and Physics in the Life Sciences and Experimental Biology (CoMPLEX), London, United KingdomGreat Ormond Street Institute of Child Health, University College London, London, United KingdomMolecular Haematology, Great Ormond Street Hospital for Children, London, United KingdomDepartment of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, DenmarkMedical Research Council Clinical Trials Unit, London, United KingdomPeter Gorer Department of Immunobiology, Kings College London, London, United KingdomDepartment of Mother and Child Health, University of Padova, Padova, ItalySection of Oncology and Immunology, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, ItalyImmunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV – IRCCS, Padova, ItalyGreat Ormond Street Institute of Child Health, University College London, London, United KingdomMolecular Haematology, Great Ormond Street Hospital for Children, London, United KingdomMedical Research Council Clinical Trials Unit, London, United Kingdom0Clinical and Research Unit of Clinical Immunology and Vaccinology, Academic Department of Pediatrics, Children Hospital Bambino Gesù - IRCCS, Rome, Italy1Division of Infection and Immunity, University College London, London, United Kingdom2Zayed Centre for Research into Rare Disease in Children, University College London, London, United KingdomGreat Ormond Street Institute of Child Health, University College London, London, United KingdomIt is intriguing that, unlike adults with HIV-1, children with HIV-1 reach a greater CD4+ T cell recovery following planned treatment cessation. The reasons for the better outcomes in children remain unknown but may be related to increased thymic output and diversity of T cell receptor repertoires. HIV-1 infected children from the PENTA 11 trial tolerated planned treatment interruption without adverse long-term clinical, virological, or immunological consequences, once antiretroviral therapy was re-introduced. This contrasts to treatment interruption trials of HIV-1 infected adults, who had rapid changes in T cells and slow recovery when antiretroviral therapy was restarted. How children can develop such effective immune responses to planned treatment interruption may be critical for future studies. PENTA 11 was a randomized, phase II trial of planned treatment interruptions in HIV-1-infected children (ISRCTN 36694210). In this sub-study, eight patients in long-term follow-up were chosen with CD4+ count>500/ml, viral load <50c/ml at baseline: four patients on treatment interruption and four on continuous treatment. Together with measurements of thymic output, we used high-throughput next generation sequencing and bioinformatics to systematically organize memory CD8+ and naïve CD4+ T cell receptors according to diversity, clonal expansions, sequence sharing, antigen specificity, and T cell receptor similarities following treatment interruption compared to continuous treatment. We observed an increase in thymic output following treatment interruption compared to continuous treatment. This was accompanied by an increase in T cell receptor clonal expansions, increased T cell receptor sharing, and higher sequence similarities between patients, suggesting a more focused T cell receptor repertoire. The low numbers of patients included is a limitation and the data should be interpreted with caution. Nonetheless, the high levels of thymic output and the high diversity of the T cell receptor repertoire in children may be sufficient to reconstitute the T cell immune repertoire and reverse the impact of interruption of antiretroviral therapy. Importantly, the effective T cell receptor repertoires following treatment interruption may inform novel therapeutic strategies in children infected with HIV-1.https://www.frontiersin.org/articles/10.3389/fimmu.2021.643189/fullHIV-1T cellsthymic outputantiretroviral treatment interruptionT cell receptorimmune repertoires